Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

Wall Street is quite bullish on BioNTech. In fact, among the 20 analysts covering it, 13 rate the stock a strong buy, while the remainder rate it a hold. Their target prices imply…

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)